Introduction
Materials and methods
Patient eligibility
Treatment
Radiotherapy
Chemotherapy
Targeted therapy
Evaluation criteria
Before treatment
Evaluation of solid tumours after treatment
Evaluation of toxicity and adverse reactions
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-OES18) evaluation
Follow-ups
Statistical analysis
Results
Characteristics
Characteristics | Total (n = 54) | NRT group (n = 28) | NCRT group (n = 26) |
---|---|---|---|
Gender | |||
Male | 42 (77.8%) | 22 (78.57%) | 20 (76.92%) |
Female | 12 (22.2%) | 6 (21.43%) | 6 (23.08%) |
Age | |||
70–79 years old | 41 (75.9%) | 16 (57.14%) | 25 (96.15%) |
More than 80 years old | 13 (24.1%) | 12 (42.86%) | 1 (3.85%) |
KPS | |||
70–80 | 28 (51.9%) | 19 (67.86%) | 9 (34.62%) |
90–100 | 26 (48.1%) | 9 (32.14%) | 17 (65.38%) |
Location of the tumor | |||
Upper esophagus | 8 (14.8%) | 2 (7.14%) | 6 (23.08%) |
Middle esophagus | 28 (51.9%) | 16 (57.14%) | 12 (46.15%) |
Lower esophagus | 18 (33.3%) | 10 (35.72%) | 8 (30.77%) |
Stage of T | |||
T1 | 3 (5.6%) | 1 (3.57%) | 2 (7.69%) |
T2 | 12 (22.2%) | 5 (17.86%) | 7 (26.92%) |
T3 | 22 (40.7%) | 14 (50.00%) | 8 (30.77%) |
T4 | 17 (31.5%) | 8 (28.57%) | 9 (34.62%) |
Stage of N | |||
N0 | 16 (29.6%) | 8 (28.57%) | 8 (30.77%) |
N1 | 18 (33.3%) | 12 (42.86%) | 6 (23.08%) |
N2 | 19 (35.2%) | 8 (28.57%) | 11 (42.31%) |
N3 | 1 (1.9%) | 0 (0) | 1 (3.84%) |
Tumor stage | |||
I | 3 (5.5%) | 1 (3.57%) | 2 (7.70%) |
II | 11 (20.4%) | 7 (25.00%) | 4 (15.38%) |
III | 21 (38.9%) | 11 (39.29%) | 10 (38.46%) |
Iva | 19 (35.2%) | 9 (32.14%) | 10 (38.46%) |
Smoking | 37 (68.52%) | 19 (67.86%) | 18 (69.23%) |
Response
Total (n = 54) | NRT group (n = 28) | NCRT group (n = 26) | |
---|---|---|---|
Complete response, n (%) | 6 (11.1%) | 2 (7.1%) | 4 (15.4%) |
Partial response, n (%) | 44 (81.5%) | 23 (82.1%) | 21 (80.8%) |
Stable disease, n (%) | 2 (3.7%) | 2 (7.1%) | 0 (0) |
Progressive disease, n (%) | 2 (3.7%) | 1 (3.6%) | 1 (3.8%) |
Objective response rate | 92.6% | 89.2% | 96.2% |
Median OS, months | 16.0 | 9.0 | 24.0 |
Median PFS, months | 10.0 | 7.0 | 17.0 |
Toxicities
Item | Grade 1–2 | ≥ Grade 3 | ||||
---|---|---|---|---|---|---|
NRT (n = 28) | NCRT (n = 26) | Total (n = 54) | NRT (n = 28) | NCRT (n = 26) | Total (n = 54) | |
Leukopenia | 19 (67.86%) | 15 (57.69%) | 34 (62.96%) | 2 (7.14%) | 6 (23.08%) | 8 (14.81%) |
Anemia | 10 (35.71%) | 13 (50.00%) | 23 (42.59%) | 0 (0) | 0 (0) | 0 (0) |
Thrombocytopenia | 4 (14.29%) | 8 (30.77%) | 12 (22.22%) | 1 (3.57%) | 4 (15.38%) | 5 (9.26%) |
Hyponatremia | 5 (17.86%) | 3 (11.54%) | 8 (14.81%) | 2 (7.14%) | 2 (7.69%) | 4 (7.41%) |
Hypoproteinemia | 27 (96.43%) | 24 (92.31%) | 51 (94.44%) | 0 (0) | 0 (0) | 0 (0) |
Nausea | 6 (21.43%) | 12 (46.15%) | 18 (33.33%) | 0 (0) | 0 (0) | 0 (0) |
Fatigue | 25 (89.29%) | 22 (84.62%) | 47 (87.04%) | 0 (0) | 0 (0) | 0 (0) |
Esophagitis | 25 (89.29%) | 25 (96.15%) | 50 (92.59%) | 2 (7.14%) | 1 (3.85%) | 3 (5.56%) |
Pneumonia | 8 (28.57%) | 17 (65.38%) | 25 (46.30%) | 1 (3.57%) | 3 (11.54%) | 4 (7.41%) |
Fever | 2 (7.14%) | 4 (15.38%) | 6 (11.11%) | 0 (0) | 0 (0) | 0 (0) |
Survival
European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire QLQ-OES18 evaluation
Treatment | |||||
---|---|---|---|---|---|
QLQ-OES18 | Before the treatment | After the treatment | Wilcoxon rank sum P | ||
Item | Mean | SD | Mean | SD | |
Dysphagia | 7.037 | 1.613 | 4.889 | 1.022 | 0.000 |
Trouble swallowing saliva | 1.259 | 0.442 | 1.000 | 0.000 | 0.000 |
Choking | 2.963 | 0.672 | 2.019 | 0.566 | 0.000 |
Eating | 5.907 | 1.773 | 5.833 | 1.145 | 0.682 |
Dry mouth | 1.315 | 0.543 | 1.833 | 0.720 | 0.000 |
Taste | 1.037 | 0.191 | 1.130 | 0.391 | 0.096 |
Cough | 1.296 | 0.603 | 1.611 | 0.712 | 0.001 |
Speech | 1.093 | 0.293 | 1.074 | 0.264 | 0.655 |
Reflux | 3.148 | 1.433 | 3.389 | 1.089 | 0.220 |
Pain | 4.093 | 1.233 | 4.574 | 1.191 | 0.035 |